PLSE
NEUTRALAnalystPulse Biosciences, Inc
This is the 2026-10-13 snapshot — the signals and analysis for PLSE as of this single trading day.
View full PLSE research hub →Analysis
Pulse Biosciences is experiencing High-Conviction Price Discovery driven by a major analyst upgrade, as Oppenheimer recently raised its price target from $35 to $60 citing competitor stumbles in the electrophysiology space, notably from Johnson & Johnson. This fundamental catalyst perfectly aligns with a suite of bullish technical signals—including a PERFECT_STACK and PANIC_REVERSAL—indicating aggressive institutional accumulation as the stock consolidates 12.1% below its recent high. With the macro backdrop in a firmly RISK_ON regime characterized by abundant liquidity and exceptionally tight credit spreads, the environment is highly supportive for speculative, high-growth medical technology assets capturing market share.
Fired Signals
Key Takeaways
- Actionable Thesis: PLSE is a high-conviction momentum play supported by aggressive analyst price target hikes and competitor setbacks that elevate its strategic value in the nsPFA market.
- Key Risk: The company is pre-profit with a staggering P/S valuation multiple; clinical viability remains a long-term risk until pivotal trial readouts in 2027.
- What to Watch: Monitor the $41.51 structural support level and any strategic partnership or M&A headlines stemming from management's recent West Coast non-deal roadshow.